Stock data
Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. (AVTX) reported revenue of US$0.06M and net income of -US$78.26M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$0.06M | — | -US$72.92M | -US$78.26M | — |
| 2024 | US$0.44M | — | -US$68.51M | -US$35.13M | — |
| 2023 | US$1.92M | — | -US$27.35M | -US$31.54M | — |
| 2022 | US$18.05M | — | -US$37.44M | -US$41.66M | — |
| 2021 | US$5.40M | — | -US$82.13M | -US$84.38M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$36.36M | — |
| 2026-03-31 | — | -US$19.63M | — |
| 2025-12-31 | — | -US$13.72M | — |
| 2025-09-30 | US$0.00M | -US$30.62M | — |
| 2025-06-30 | — | -US$20.77M | — |
| 2025-03-31 | — | -US$13.15M | — |
| 2024-12-31 | US$0.19M | -US$35.34M | — |
| 2024-09-30 | US$0.25M | US$23.04M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.